AnaptysBio reported diluted third-quarter earnings of $0.11 per share, below the Zacks consensus estimate of $0.41 and down from $0.52 in the same period last year. Revenue was $30.27 million, a 60% year-over-year decline, but topped analyst estimates for the quarter. Total cash and investments reached $153 million. One supplied item says earnings beat estimates by $0.75 per share, contradicting the other reported figures.
The company attributed the decline to the absence of a $50 million milestone payment recorded a year earlier, while quarterly Jemperli royalties rose 11% and earnings and liquidity declined.
Read the full storyNet income declined to $3.876 million from $15.113 million a year earlier, while Jemperli royalties rose despite a drop in total collaboration revenue.
Revenue fell from $76.3 million a year earlier without the benefit of a large milestone payment, while quarterly Jemperli royalties rose 11% and global sales grew.